体内CAR-Tin vivo CAR-T
体内重编程T细胞
每条都摘自下方编号的来源原文;只写事实,不写预测或建议。
未定事项
- 辉瑞取得许可的三项自身免疫疾病体内CAR-T项目均处于IND申报前阶段。1
Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases.
相关卡片
- 2026-11-18辉瑞付星锐医药 3.3 亿美元首付款,取得体内 CAR-T 疗法独家许可